Home > Oncology > Novel nanobiologic trains immunity, curbs tumor growth in mice

Novel nanobiologic trains immunity, curbs tumor growth in mice

Journal
Cell
Reuters Health - 02/11/2020 - A bone marrow-targeted nanobiologic, MTP(10)-HDL, induced trained immunity and potentiated checkpoint inhibition in a mouse melanoma model, suggesting the approach could eventually be used as anti-cancer therapy, researchers say. "Our current estimate is to reach human trials between two and four years from now," Dr. Willem Mulder of Eindhoven University of Technology in The Netherlands and the Icahn School of Medicine at Mount Sinai in New York City told Reuters Health by email. "Manufacturing is, of course, a critical hurdle, and we have developed a process that is scalable and good manufacturing practice-compatible," he said. "Thereafter, pharmacokinetic and toxicity studies should advance the program to an Investigational New Drug Application." As reported in Cell, Dr. Mulder and colleagues delivered MTP-HDL intravenously to mice with melanoma. The resulting induction of trained immunity led to myelopoiesis, the production of...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on